Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction

International Journal of Cardiology

Volumn 208, Issue , 2016, Pages 109-114

  Chen, Wei Ren ^a   Tian, Feng ^a   Chen, Yun Dai ^a   Wang, Jing ^a   Yang, Jun Jie ^a   Wang, Zhi Feng ^a   Da Wang, Jin ^a   Ning, Qing Xiu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Acute ST segment elevation myocardial infarction; Glucagon like peptide 1; No reflow; Percutaneous coronary intervention; Reperfusion injury

Indexed keywords

C REACTIVE PROTEIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; INTRAAORTIC BALLOON PUMP; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; DIAGNOSTIC IMAGING; FOLLOW UP; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PROSPECTIVE STUDY; TREATMENT OUTCOME; TRENDS;

AGED; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84959306499     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.12.009     Document Type: Article

References (44)

1. E.C. Keeley, J.A. Boura, and C.L. Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 2003 13 20
2. O. Muller, C. Trana, and E. Eeckhout Myocardial no-reflow treatment Curr. Vasc. Pharmacol. 11 2013 278 285
3. M. Magro, T. Springeling, R.J. van Geuns, and F. Zijlstra Myocardial 'no-reflow' prevention Curr. Vasc. Pharmacol. 11 2013 263 277
4. D. Aronson, H. Hammerman, M.R. Kapeliovich, A. Suleiman, Y. Agmon, and et al. Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function Diabetes Care 30 2007 960 966
5. J.W. Wang, Y.D. Chen, C.H. Wang, X.C. Yang, X.L. Zhu, and et al. Development and validation of clinical risk score predicting the no-reflow phenomenon inpatients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction Cardiology 124 2013 153 160
6. C.H. Wang, Y.D. Chen, X.C. Yang, L.F. Wang, H.S. Wang, and et al. The effect of admission hyperglycemia on coronary reflow in primary percutaneous coronary intervention Zhonghua Nei Ke Za Zhi 50 2011 303 306
7. J. Lønborg, N. Vejlstrup, H. Kelbæk, H.E. Bøtker, W.Y. Kim, and et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur. Heart J. 33 2012 1491 1499
8. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, and et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
9. A. Ceriello, A. Novials, E. Ortega, S. Canivell, L. La Sala, and et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes Diabetes Care 36 2013 2346 2350
10. L. Timmers, J.P. Henriques, D.P. de Kleijn, J.H. Devries, H. Kemperman, and et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury J. Am. Coll. Cardiol. 53 2009 501 510
11. W. Ganz The thrombolysis in myocardial infarction (TIMI) trial N. Engl. J. Med. 313 1985 1018
12. A.W. van't Hof, A. Liem, H. Suryapranata, J.C. Hoorntje, M.J. de Boer, and et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group Circulation 97 1998 2302 2306
13. G. Niccoli, F. Burzotta, L. Galiuto, and F. Crea Myocardial no-reflow in humans J. Am. Coll. Cardiol. 54 2009 281 292
14. A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro III, and et al. CKD-EPI (chronic kidney disease epidemiology collaboration). A new equation to estimate glomerular filtration rate Ann. Intern. Med. 150 2009 604 612
15. P.J. Best, D.N. Reddan, P.B. Berger, L.A. Szczech, P.A. McCullough, and et al. Cardiovascular disease and chronic kidney disease: insights and an update Am. Heart J. 148 2004 230 242
16. W.L. Miller, R.S. Wright, J.P. Grill, and S.L. Kopecky Improved survival after acute myocardial infarction in patients with advanced Killip class Clin. Cardiol. 23 2000 751 758
17. T.J. Rosol On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice Toxicol. Pathol. 41 2013 303 309
18. S.R. Ahmad, and J. Swann Exenatide and rare adverse events N. Engl. J. Med. 358 2008 1970 1971
19. J.S. Woo, W. Kim, S.J. Ha, J.B. Kim, S.J. Kim, and et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study Arterioscler. Thromb. Vasc. Biol. 33 2013 2252 2260
20. K. Kikugawa, T. Kojima, S. Yamaki, and H. Kosugi Interpretation of the thiobarbituric acid reactivity of rat liver and brain homogenates in the presence of ferric ion and ethylediaminotetraacetic acid Anal. Biochem. 202 1992 249 255
21. X.W. Jia, X.H. Fu, J. Zhang, X.S. Gu, W.Z. Fan, and et al. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome Chin. Med. J. 122 2009 659 664
22. S. Matsumoto, M. Yamazaki, M. Kadono, H. Iwase, K. Kobayashi, and et al. Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes J. Clin. Biochem. Nutr. 53 2013 68 72
23. M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, and et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744
24. J.J. Popma, N. Cox, K.E. Hauptmann, N. Reifart, R. Virmani, and et al. Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention Catheter. Cardiovasc. Interv. 57 2002 125 134
25. T. Nakamura, N. Kubo, Y. Seki, N. Ikeda, T. Ishida, and et al. Effects of a distal protection device during primary stenting in patients with acute anterior myocardial infarction Circ. J. 68 2004 763 768
26. R. Hofmann, A. Kypta, K. Kerschner, M. Grund, C. Steinwender, and et al. Thrombus aspiration prior to primary angioplasty in acute myocardial infarction: estimation of rescued myocardial tissue by return of ST-segment elevation Clin. Cardiol. 27 2004 451 454
27. G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, and et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction N. Engl. J. Med. 344 2001 1895 1903
28. H. Kunichika, O. Ben-Yehuda, S. Lafitte, N. Kunichika, B. Peters, and et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion J. Am. Coll. Cardiol. 43 2004 276 283
29. Y. Taniyama, H. Ito, K. Iwakura, T. Masuyama, M. Hori, and et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction J. Am. Coll. Cardiol. 30 1997 1193 1199
30. A.R. Assali, S. Sdringola, M. Ghani, A.E. Denkats, A. Yepes, and et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no-reflow phenomenon" Catheter. Cardiovasc. Interv. 51 2000 27 31
31. M. Marzilli, E. Orsini, P. Marraccini, and R. Testa Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction Circulation 101 2000 2154 2159
32. H. Ito, Y. Taniyama, K. Iwakura, N. Nishikawa, T. Masuyama, and et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction J. Am. Coll. Cardiol. 33 1999 654 660
33. M. Monami, I. Dicembrini, C. Nardini, I. Fiordelli, and E. Mannucci Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials Diabetes Obes. Metab 16 2014 38 47
34. B. Hirshberg, and A. Katz Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective Curr. Diab. Rep. 15 2015 87
35. A. Undas, I. Wiek, E. Stêpien, K. Zmudka, and W. Tracz Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome Diabetes Care 31 2008 1590 1595
36. J.Y. Park, N. Takahara, A. Gabriele, E. Chou, K. Naruse, and et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation Diabetes 49 2000 1239 1248
37. W.R. Chen, X.Q. Shen, Y. Zhang, Y.D. Chen, and S.Y. Hu Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction Endocrine 2015 1 11 10.1007/s12020-015-0798-0 (16 November)
38. M.L. Villanueva-Peñacarrillo, J. Puente, A. Redondo, F. Clemente, and I. Valverde Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models Endocrine 15 2001 241 248
39. T. Zhao, P. Parikh, S. Bhashyam, H. Bolukoglu, I. Poornima, and et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts J. Pharmacol. Exp. Ther. 317 2006 1106 1113
40. S.C. Bekkers, S.K. Yazdani, R. Virmani, and J. Waltenberger Microvascular obstruction: underlying pathophysiology and clinical diagnosis J. Am. Coll. Cardiol. 55 2010 1649 1660
41. R. Jaffe, T. Charron, G. Puley, A. Dick, and B.H. Strauss Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention Circulation 117 2008 3152 3156
42. B.B. Dokken, L.R. La Bonte, G. Davis-Gorman, M.K. Teachey, N. Seaver, and et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents Horm. Metab. Res. 43 2011 300 305
43. W.R. Chen, S.Y. Hu, Y.D. Chen, Y. Zhang, G. Qian, and et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention Am. Heart J. 170 2015 845 854
44. T. Nyström, A.T. Gonon, A. Sjöholm, and J. Pernow Glucagon-like peptide-relaxes rat con-duit arteries via an endothelium-independent mechanism Regul. Pept. 125 2005 173